嵌合抗原受体
肿瘤微环境
细胞疗法
癌症研究
癌症免疫疗法
主要组织相容性复合体
细胞因子释放综合征
抗原
医学
癌症
免疫学
免疫疗法
生物
免疫系统
细胞
遗传学
内科学
作者
Yiqing Wang,Yan-Ruide Li
出处
期刊:Current Pharmaceutical Biotechnology
[Bentham Science]
日期:2024-02-04
卷期号:25 (15): 2001-2011
被引量:1
标识
DOI:10.2174/0113892010265228231116073012
摘要
: Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has emerged as a revolutionary approach for cancer treatment, especially for hematologic cancers. However, CAR-T therapy has some limitations, including cytokine release syndrome (CRS), immune cellassociated neurologic syndrome (ICANS), and difficulty in targeting solid tumors and delivering allogeneic cell therapy due to graft-versus-host disease (GvHD). Therefore, it is important to explore other cell sources for CAR engineering. Invariant natural killer T (iNKT) cells are a potential target, as they possess powerful antitumor ability and do not recognize mismatched major histocompatibility complexes (MHCs) and protein antigens, thus avoiding the risk of GvHD. CAR-engineered iNKT (CAR-iNKT) cell therapy offers a promising new approach to cancer immunotherapy by overcoming the drawbacks of CAR-T cell therapy while retaining potent antitumor capabilities. This review summarizes the current CAR-iNKT cell products, their functions and phenotypes, and their potential for off-the-shelf cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI